James Ahlers
Plus aucun poste en cours
Profil
James M.
Ahlers formerly worked at Titan Pharmaceuticals, Inc., as Director-Finance & Administration, Ansan Pharmaceuticals, Inc., as Director-Finance & Administration, Tularik, Inc., as Financial Consultant, Genesoft Pharmaceuticals, Inc., as Financial Consultant, Cytokinetics, Inc., as Financial Consultant, RenovoRx, Inc., as Chief Financial Officer from 2022 to 2024, Deloitte & Touche LLP, as Member-Audit Department, Medco Behavioral Care Corp., as Manager-Financial Planning & Analysis, Intarcia Therapeutics, Inc., as Chief Financial Officer, VP-Operations & Finance from 2002 to 2019, and Intensity Therapeutics, Inc., as Executive Vice President-Corporate Finance from 2023 to 2024.
Mr. Ahlers received his undergraduate degree from the University of San Francisco.
Anciens postes connus de James Ahlers
| Sociétés | Poste | Fin |
|---|---|---|
| INTENSITY THERAPEUTICS, INC. | Corporate Officer/Principal | 21/05/2024 |
| RENOVORX, INC. | Directeur Financier/CFO | 05/02/2024 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Directeur Financier/CFO | 01/11/2019 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Formation de James Ahlers
| University of San Francisco | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| INTENSITY THERAPEUTICS, INC. | Health Technology |
| RENOVORX, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
| Genesoft Pharmaceuticals, Inc. | Commercial Services |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Medco Behavioral Care Corp.
 Medco Behavioral Care Corp. Pharmaceuticals: MajorHealth Technology Medco Behavioral Care Corp. specializes in behavioral health management. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Ansan Pharmaceuticals, Inc. | Health Technology |
